Serum metalloproteinase-9 is related to COPD severity and symptoms - cross-sectional data from a population based cohort-study
Open Access
- 21 February 2015
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 16 (1) , 1-9
Abstract
Chronic obstructive pulmonary disease, COPD, is an increasing cause of morbidity and mortality worldwide, and an imbalance between proteases and antiproteases has been implicated to play a role in COPD pathogenesis. Matrix metalloproteinases (MMP) are important proteases that along with their inhibitors, tissue inhibitors of metalloproteinases (TIMP), affect homeostasis of elastin and collagen, of importance for the structural integrity of human airways. Small observational studies indicate that these biomarkers are involved in the pathogenesis of COPD. The aim of this study was to investigate serum levels of MMP-9 and TIMP-1 in a large Swedish population-based cohort, and their association with disease severity and important clinical symptoms of COPD such as productive cough. Spirometry was performed and peripheral blood samples were collected in a populations-based cohort (median age 67 years) comprising subjects with COPD (n = 594) and without COPD (n = 948), in total 1542 individuals. Serum MMP-9 and TIMP-1 concentrations were measured with enzyme linked immunosorbant assay (ELISA) and related to lung function data and symptoms. Median serum MMP-9 values were significantly higher in COPD compared with non-COPD 535 vs. 505 ng/ml (P = 0.017), without any significant differences in serum TIMP-1-levels or MMP-9/TIMP-1-ratio. In univariate analysis, productive cough and decreasing FEV1% predicted correlated significantly with increased MMP-9 among subjects with COPD (P = 0.004 and P = 0.001 respectively), and FEV1% predicted remained significantly associated to MMP-9 in a multivariate model adjusting for age, sex, pack years and productive cough (P = 0.033). Productive cough and decreasing FEV1 were each associated with MMP-9 in COPD, and decreasing FEV1 remained significantly associated with MMP-9 also after adjustment for common confounders in this population-based COPD cohort. The increased serum MMP-9 concentrations in COPD indicate an enhanced proteolytic activity that is related to disease severity, and further longitudinal studies are important for the understanding of MMP-9 in relation to the disease process and the pathogenesis of different COPD phenotypes.Keywords
This publication has 49 references indexed in Scilit:
- Influence of Age, Past Smoking, and Disease Severity on TLR2, Neutrophilic Inflammation, and MMP-9 Levels in COPDMediators of Inflammation, 2013
- Matrix Metalloproteinase-9 -1562C/T Promoter Polymorphism Confers Risk for COPD: A Meta-AnalysisPLOS ONE, 2013
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiencyRespiratory Research, 2011
- Pathogenic triad in COPD: oxidative stress, protease–antiprotease imbalance, and inflammationInternational Journal of Chronic Obstructive Pulmonary Disease, 2011
- Ageing and smoking contribute to plasma surfactant proteins and protease imbalance with correlations to airway obstructionBMC Pulmonary Medicine, 2011
- Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or IIIRadiology and Oncology, 2011
- Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research studyBMC Pulmonary Medicine, 2010
- Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary diseaseRespiratory Medicine, 2009
- Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsiesEuropean Respiratory Journal, 2007